TAG demands immediate action by the National Institutes of Health (NIH) to provide Congressionally appropriated and committed funding to the HIV clinical research networks (ACTG, HPTN, HVTN, IMPAACT).
Lifesaving scientific research on prevention, testing, treatment and care for people living with HIV and tuberculosis (TB) in South Africa is under serious threat due to funding suspensions and grant terminations from the United States (US) government.
What does TAG's work look like in action? Here we step into a day in the life of our TB program co-directors, Mike Frick and Lindsay McKenna, to see how their advocacy for better TB research and policy — made possible by your support — are driving meaningful change to save lives and empower communities affected by TB.
Treatment Action Group (TAG) decries the vicious and inchoate attacks on HHS since the advent of the new administration, which have escalated significantly over the past week.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.
TAG is deeply concerned about the Trump administration’s potential plans to eliminate vital HIV programs at the CDC’s Division of HIV Prevention (DHP) and other programs in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).
Treatment Action Group (TAG) is disgusted and appalled by the new presidential administration’s flagrant attack on science.
Treatment Action Group (TAG) fiercely condemns the new presidential administration’s deadly and hateful attack on people living with HIV and their communities at home and around the world.
This title of this page is one of the quotes by Mark Harrington from his recent appearance on +Life Media with TAG board member Karl Schmid. We rate this video absolutely must watch!
TAG was proud to sign on to this 2/3/25 letter created by HIV Health Care Access Working Group (HHCAWG) of the Federal AIDS Policy Partnership (FAPP).